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OBJECTIVE 
To analyze the venous endothelial function in Chagas’ 
disease patients without heart failure.
METHODS 
The Chagas’ disease Group (G1) was composed by 14 
women and 2 men aged 46 ± 2,7 and the Control Group 
(G0) by 7 women and 1 man matched by age, weight 
and height. Dorsal Hand Vein Compliance Technique was 
used to evaluate the venous endothelial function. Crescent 
doses of phenylephrine were infused to get a 70% pre-
constriction of the vein; after that, acetylcholine and sodium 
nitroprusside were respectively administrated to analyze the 
endothelium-dependent and -independent venodilation.
RESULTS 
No significant systemic hemodynamic changes 
were observed in both groups during the experiment. 
The necessary phenylephrine dose to reach 70% pre-
constriction of the vein was signifi cantly higher in the 
G1 (1116 ± 668,2 ng/ml) compared to G0 (103 ± 28 
ng/ml) p = 0,05. The endothelium-dependent venous 
dilation was signifi cantly lower in G1 (65,5 ± 8%) 
compared to G0 (137 ± 20 %) p = 0,009. No difference 
was observed in the endothelium-independent venous 
dilatation between groups.
CONCLUSION 
Patients with Chagas’ disease without heart failure 
presented venous endothelial dysfunction.
KEY WORDS 
Endothelium, Chagas’ disease, system venous, 
cardiovascular disease.
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Chagas disease is still a major public health problem. 
It is estimated that between four and six million Brazilians 
have the disease. It is a chronic debilitating disease that 
provokes premature disability and is one of the main 
causes of early retirement in Brazil1,2. Considering the 
clinical seriousness of its evolution and the socioeconomic 
impact, Chagas disease has been targeted as a study topic 
by numerous, renowned researchers seeking to improve 
the available information about the disease3-9. 
It has been clearly established that Chagas disease 
is extremely heterogeneous in respect to the severity 
of the myocardial condition. Even though signifi cant 
physiopathological aspects related to the onset and 
progression of the Chagas cardiopathy have been 
established, there are still many factors that need to be 
clarifi ed. Various studies on Chagas patients without heart 
disease have demonstrated the presence of lesions in the 
area of the heart’s innervation and others have indicated 
defi ciencies in the autonomic control of heart rate and 
blood pressure9-12. More recent studies have demonstrated 
that the refl ex control of peripheral vascular reactivity is 
also compromised in Chagas patients with preserved 
ventricular function9,12.
We have to consider that the control of peripheral 
tonus and reactivity does not only depend on neural 
control but also on adequate endothelial cell function. 
Endothelial dysfunction has been proposed as one of the 
mechanisms for the onset, maintenance and progression 
of various cardiovascular diseases such as hypertension, 
atherosclerosis and heart failure13-15. 
During the course of the Chagas disease infection, 
parasites have been observed in the microvascular 
endothelia of the aorta and coronary arteries before 
detection of the parasitemia10,16,17. Cultures of endothelial 
cells infected with T. cruzi show complex alterations in 
mechanisms that are critical to maintain normal vascular 
function18-20. Based on this, endothelium cell dysfunction 
in the coronary arteries has been determined to be one 
of the primary mechanisms observed in patients with 
Chagas disease, and could be related to the myocardial 
lesion. 
The evaluation of endothelial function using 
concentrations of endothelium produced substances 
and infl ammatory markers suggests the presence of 
endothelial dysfunction in Chagas patients with preserved 
vascular function21-24.
There are few documented studies using endothelium-
dependent vasodilation analysis to evaluate peripheral 
endothelial function in Chagas patients. Two studies 
conducted on Chagas patients without heart failure are 
controversial as to whether or not there is endothelial 
dysfunction in the peripheral artery region (brachial 
artery)4,5. There are no reports that confi rm whether 
or not Chagas patients present venous endothelial 
dysfunction. 
The objective of this study is to investigate whether or 
not Chagas patients with preserved ventricular function 
present venous endothelial dysfunction. 
METHODS
This study was approved by the Research Ethics 
Committee of the São Paulo Federal University – Unifesp 
and the Heart Institute - InCor (Protocol 0425/02).
The individuals with Chagas disease were selected 
from the patients at the outpatient clinic of the Heart 
Institute’s (InCor) Cardiomyopathy Unit of the University 
of São Paulo School of Medicine between February 2003 
and February 2005. The endothelial function evaluation 
was conducted at the Laboratory of Clinical Investigation 
of InCor’s Hypertension Unit. All study participants were 
briefed on the objectives of the study and signed the free 
and informed consent form. 
All the Chagas patients had positive serological 
tests for Chagas disease (indirect hemaglutination and 
immunofluorescence) and were from the disease’s 
endemic zone. Sixteen patients were selected based on 
the following inclusion criteria: did not present symptoms 
related to the cardiac or gastrointestinal forms of Chagas 
disease or any other disease; were not using medication; 
had a clinical examination within normal limits; had left 
ventricular function greater than 60% of the ejection 
fraction on the Doppler echocardiogram test (Teichholz 
and associates method25); had CBC and biochemical 
(glucose, cholesterol and triglycerides) test results within 
normal ranges.
From the sixteen Chagas patients, eight presented 
a normal electrocardiogram and eight presented an 
altered electrocardiogram: right bundle branch block, 
bradycardia and/or block of the anterosuperior division 
of the left bundle branch (Minnesota code modifi ed for 
Chagas disease26). 
Venous endothelial function was evaluated using the 
dorsal hand vein compliance technique27-30. During the 
evaluation, the individuals remained in the supine position 
with one of the forearms placed on a support forming 
an upward 30 degree slope from the horizontal. A 23G 
butterfl y needle was inserted in a vein on the dorsum of 
the hand and saline solution was administered using a 
Harvard infusion pump (Harvard Apparatus Inc. South 
Natick, Mass) for 30 minutes at 0.3 ml/min, to allow the 
vein to restore its tone following the constriction caused 
by the insertion of the needle. 
The transducer, sensitive enough to detect minimal 
linear displacements (TDLV, Shaevitz Engineering, 
Pennsauken, NJ) was placed on dorsum of the hand and 
fi xed securely to the skin with adhesive tape. One of the 
ends of the metallic rod that slides through the transducer 
was placed over the vein to be studied, less than 1 cm 
from the end of the intravenous needle. 
Vertical displacement of the rod according to the degree 
of vein dilation or constriction generated a transducer 
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signal that was amplifi ed and recorded on graph paper.
Measurements of the vein diameter were conducted 
after infl ating a sphygmomanometer cuff to 40 mmHg 
which was placed on the same arm. The vein diameter 
variations were calculated by the percentage difference 
of the metallic rod positioning and graphic recording was 
generated before and after cuff infl ation.
After the saline infusion, phenylephrine was infused in 
progressive doses until a 70% constriction was obtained 
(VC70%). Each of the progressive doses of phenylephrine 
(75 to 25,000 ng/ml) were administered for seven minutes. 
Once the desired venoconstriction was obtained, which 
established the base line for venous vascular response 
evaluation, the phenylephrine dosage was maintained and 
administered for the duration of the study. 
To evaluate endothelium-dependent venodilation, 
seven progressive doses of acetylcholine (3.6 to 3,600 
ng/ml) were administered at an infusion rate of 0.3 
ml/min, for a period of three minutes each. Maximum 
venodilation and the required dosages to attain this effect 
were compared between the groups. 
 At the end of this phase, a 30 minute interval was 
taken for the acetylcholine effect to wear off. Next, three 
progressive doses (156 to 3,125 ng/ml) of sodium 
nitroprusside were administered at an infusion rate of 
0.3 ml/min, for a period of three minutes each, using 
the method described earlier to obtain preconstriction 
(VC70%). Maximum venodilation and the dosages 
required to achieve this effect were compared between 
the groups.
RESULTS
Demographic characteristics of the Chagas and control 
groups - In relation to age, weight, height and body mass 
index (BMI) there were no signifi cant differences between 
the control (G0) and Chagas (G1) groups. Additionally, 
the BMI values were within the healthy range. 
In relation to gender, the distribution was similar 
between the groups with 12.5% male and 77.5% female 
in the control (G0) and Chagas (G1) groups. 
The values of fasting glucose, total cholesterol, 
triglycerides, hemoglobin and hematocrit did not 
present any signifi cant statistical differences between 
the groups. 
Both groups attained similar venous preconstriction 
values, in the range of 70%, that was adequate for 
the subsequent tests. However, there was a signifi cant 
difference between the groups in relation to the dosages 
of phenylephrine required to obtain the desired level of 
venoconstriction. In comparison to the control group, 
the Chagas patients required signifi cantly higher doses 
of phenylephrine to obtain the satisfactory degree of 
venoconstriction.
In relation to the administration of acetylcholine, it was 
observed that the maximum venodilation values for the 
Chagas patients were roughly 50% lower than the control 
group. The average acetylcholine dosages in relation to 
maximum venodilation were similar for the two groups. 
Maximum venodilation values with the administration 
of sodium nitroprusside (endothelium-independent dilation 
evaluation) did not reveal any signifi cant differences 
between the groups or the dosages of agent used. 
DISCUSSION
The major fi nding of our study was the confi rmation 
that patients with Chagas disease without heart failure 
present signifi cantly lower maximum venodilation values 
with the administration of acetylcholine and normal 
maximum venodilation values with the administration 
of sodium nitroprusside. Combined analysis of these 
data indicates venous endothelial dysfunction in Chagas 
patients with preserved ventricular function. 
Another item that deserves emphasis was the 
observation that Chagas patients require signifi cantly 
Table 1 – Demographic and biochemical characteristics of the study groups: 
control group (G0) and Chagas group (G1)
Group 0 (n = 8) Group 1 (n = 16) p < 0.05
Age (years) 43 ± 4.5 46 ± 2.7 ns
Gender 1M/7F 2M/14F ns
Weight (kg) 65.3 ± 3.4 63.3 ± 2.3 ns
Height (m) 1.66 ± 0.02 1.63 ± 0.01 ns
BMI (kg/m²) 23.5 ± 0.8 24 ± 0.7 ns
Systolic BP (mmHg) 115.8 ± 4.6 122.8 ± 6.53 ns
Diastolic BP (mmHg) 73.5 ± 3.4 76 ± 4.2 ns
Fasting Glucose (mg/dl) 89 ± 1 97.2 ± 2.8 ns
Total Cholesterol (mg/dl) 209.2 ± 10 201.4 ± 3.2 ns
Triglycerides (mg/dl) 101.1 ± 25.5 121.6 ± 25 ns
Hemoglobin (g/100ml) 13.4 ± 0.29 13.1 ± 0.3 ns
The values represent the mean  ± standard error, Student’s t-test, ns = not signifi cant; BMI – body mass index
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higher doses of phenylephrine to obtain venoconstriction, 
suggesting lower alpha-adrenergic receptor sensitivity in 
the venous system of these patients. 
The endothelial cells produce the most potent 
vasodilator ever discovered, nitric oxide (NO) that was 
described by Furchgott and Zawadzki in 1980 and 
identified as a nonprostanoid, labile and diffusible 
substance that mediates the endothelium-dependent 
vasorelaxation. The formation of NO by endothelium 
cells performs a critical role in maintaining the balance 
between vasoconstriction and vasodilation in the arterial 
and venous homeostasis process31.
Numerous studies describe the vasodilation changes in 
the dorsal hand vein after local infusion of acetylcholine 
or bradykinin in patients with cardiovascular risk 
factors that are known to affect artery endothelium27-30. 
Additionally, treatments that improve artery endothelial 
function also improve endothelial function in the venous 
system29. Studying the venous endothelia enables 
a better understanding of the circulatory regulation 
process and the effect of treatments on the modulation 
of peripheral regulation. 
The venous system plays an important role in the 
homeostasis of the circulatory system and alterations in 
this system can lead to compromised venous return and 
circulation, since the changes in the vascular system 
could potentially affect cardiac function regulation and 
cause heart failure32. To date no previous studies had 
detected peripheral venous system alterations, or more 
importantly, venous endothelial responses in Chagas 
disease patients.
Recent studies have demonstrated increased plasma 
levels of the cytotoxic endothelial moderators, tumor 
necrosis factor alpha (TNF-α) and interleukin 10 (IL 
-10) in asymptomatic patients with Chagas disease, 
suggesting that a prolonged production of these factors 
could be related to the cardiomyopathy progression in 
these patients21-23. Circulating anti-cholinergic receptor 
antibodies have also been found in chronic Chagas 
cardiopathy patients33-36. Considering these fi ndings 
and their repercussions on vascular tonus modulation, 
we can speculate a possible relation between them and 
the results in our study since these factors can lead to 
endothelial dysfunction.
Experimental studies on the distribution and different 
responses to pharmaceutical agents are fundamental to 
understand the venous system physiopathology. In this 
study we demonstrate that the alpha adrenergic sensitivity, 
evaluated during the administration of phenylephrine, was 
diminished in the Chagas patients when compared to 
the control group. Comparisons of receptor distribution 
and venous response to the administration of adrenergic 
agents using noradrenaline (non-selective α agonist), 
phenylephrine (α-1 agonist) and azepexol (α-2 agonist) 
demonstrated that vasoconstriction was induced by all 
the agents and suggests that the veins are responsive to 
all alpha receptors. Since the response to phenylephrine 
was more accentuated, the author suggested that the 
distribution of α-1 receptors was prominent in the veins 
37. In humans with Chagas disease the sympathetic 
innervation of the heart, evaluated using scintigraphy 
with radio-isotopes, was found to be diminished as 
reported by Simões and associates38. An indirect study of 
peripheral sympathetic innervation using catecholamine 
concentrations or blood pressure variations indicates 
alterations in the sympathetic function39. Data from 
an earlier study conducted by our group with a similar 
population of Chagas patients revealed an increased 
peripheral chemorefl ex response9, indicating alterations 
in the peripheral sympathetic response of these patients. 
This alteration in sympathetic activity could be related to 
the reduced sensitivity to adrenergic agonists, as observed 
in this study.
Based on our fi ndings, we can conclude that venous alpha 
adrenergic sensitivity is diminished and that endothelial 
response mediated by muscarinic receptors is lowered, 
which is indicative of venous endothelial dysfunction in 
Chagas patients with preserved ventricular function.
Table 2 – Average of the maximum venodilation and required dosages of phenylephrine, acetylcholine and  
sodium nitroprusside for the study groups: control group (0) and Chagas group (1)
Group 0 (n = 8) Group 1 (n = 16) p
VC70% 68.5 ± 4.5 76.8 ± 2.4 0.15
Phenylephrine doses for VC70% 103 ± 28 1116 ± 668 ** 0.05
Max.VD with Acetyl. 137 ± 20 65.5 ± 8 ** 0.009
Acetyl. doses (ng/ml) for Max.VD 1980 ± 390 2092 ± 366 0.85
Max.VD with SNP 169 ± 25.5 163 ± 19 0.83
SNP doses (ng/ml) for MaxVD 1425 ± 436 1004 ± 223 0.39
The values represent the mean ± standard error;VC = venoconstriction; MaxVD = maximum venodilation; Acetyl. = acetylcholine; SNP = sodium 
nitroprusside
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